Adlai Nortye Ltd.

NASDAQ:ANL

Biotechnology

Healthcare
$8.74 -1.07%

-$0.11 today

Market cap
$463.92M
Beta
0.99
P/E (TTM)
-3.0
EPS (TTM)
-$3.33
52W Low $0.88High $17.25

Volume 0.45M

Average 0.35M

ANL Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Adlai Nortye Ltd.NASDAQ: ANL

Other Income / Expenses · Q2 FY2024 · quarter ended Jun 2024

Other income / expenses turns positive

Q2 FY2024 other income / expenses was $815.5K, compared with -$46.54M a year earlier. Trailing-twelve-month other income / expenses was $11.25M. Over 3 fiscal years it compounded at -72.8% a year.

Context

  • Other income / expenses amounted to 3.4% of revenue in FY2025.
  • Other income / expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near $815.5K or moves back toward the trailing-twelve-month quarterly average of $2.81M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2024
$815.5K+0.0% QoQ
Last fiscal yearDec 2025
$170K-83.9% YoY
LTMJun 2024
$11.25M+121.6% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+101.8%——
1 year-83.9%——
3-year CAGR-72.8%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
170K USD
Year-over-year change
-83.9%

Other Income / Expenses vs competitors

How ANL compares with its peers on the latest reported figures

  • ANL's LTM Jun 2024 other income / expenses of $11.25M is the highest of the 7 companies compared; the peer median is $1.15M.
  • Other income / expenses amounts to 173.3% of revenue for ANL, versus a peer median of 17.2%.
ANL Competitors Peer median
Other Income / Expenses for ANL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANLAdlai Nortye Ltd.LTM Jun 2024$11.25M —-72.8%173.3%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$5.44M -67.9%-1.8%19.3%
CGENCompugen Ltd.LTM Mar 2026$4.18M -19.6%+32.8%5.8%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$3.76M +136.9%——
APLMApollomics, Inc.FY2025-$1.46M +87.2%—17.2%
NUVBNuvation Bio Inc.LTM Jun 2026-$12.2M -156.1%-18.4%7.2%
VSTMVerastem, Inc.LTM Mar 2026-$23.11M -31.1%—46.6%
Peer median (excluding ANL) $1.15M-25.4%-1.8%17.2%

Competitors are the stored peer set for ANL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.73M0005M
Cost of Revenue00000
Gross Profit45.73M0005M
Gross Margin100.0%———100.0%
Research & Development42.11M54.49M58.15M44.92M32.83M
Selling, General & Admin12.45M12.43M14.82M9.44M7.79M
Operating Expenses54.37M67.27M72.55M52.93M40.7M
Depreciation & Amortization1.83M2.04M2.22M1.87M1.41M
EBITDA(53.51M)(56.32M)(106.22M)(48.06M)(32.63M)
EBITDA Margin-117.0%———-652.5%
Operating Income(8.65M)(67.27M)(72.55M)(52.93M)(35.7M)
Operating Margin-18.9%———-714.0%
Interest Income32K550K62K01K
Interest Expense1.34M433K791K1.94M1.49M
Other Income / Expenses(48.03M)8.48M(36.68M)1.06M170K
Income Before Tax(56.68M)(58.79M)(109.23M)(51.87M)(35.53M)
Pre-Tax Margin-124.0%———-710.6%
Income Tax Expense00000
Net Income(56.68M)(58.79M)(109.23M)(51.87M)(35.53M)
Net Margin-124.0%———-710.6%
EPS (Basic)(6.66)(6.93)(15.42)(4.89)(3.33)
EPS (Diluted)(6.66)(6.93)(15.42)(4.89)(3.33)
Weighted Avg Shares8.48M8.48M6.8M10.64M10.66M
Weighted Avg Shares (Diluted)8.48M8.48M6.8M10.64M10.66M

Adlai Nortye Ltd.

NASDAQ:ANL

Intrinsic Alpha fair value

Locked

Current Price

$8.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.